Each one in plain English, with the numbers worked through for a shareholder.
6 Dec 2022other material event▼ Bad
Files unaudited Q3 2022 statements, closing the catch-up for the year. Q3 revenue was $1,573,809 against $405,707, with a net loss of $457,066. Cash fell to $469,712 at September 30, 2022, from $866,170 at year-end 2021. Shareholders' deficiency was $5,352,282 and the going-concern note remains. Falling cash alongside continuing losses raises financing risk (an inference).
Files unaudited Q2 2022 statements as the catch-up continues. Q2 revenue was $1,553,980 against $861,826, and Q2 net income was $2,165,855, helped by gains of $2,109,836 on warrant liability and $1,450,057 on the conversion feature. Six-month net income was only $845. Cash fell to $793,935 and shareholders' deficiency was $4,949,834, with a going-concern note. The Q2 profit came from non-cash fair-value gains, not operations: loss from operations was $1,236,941.
Files unaudited Q1 2022 statements, another catch-up filing after the late 2021 annual report. Revenue was $1,106,950 against $1,958,802 a year earlier, and net loss was $2,165,010 against $25,213,556. At March 31, 2022 cash was $2,518,743 and shareholders' deficiency was $7,384,047, with a going-concern note. The auditors did not review the statements. Revenue fell, and the deficiency widened from $6,392,941 at December 31, 2021.
Files audited 2021 results, more than ten months late. Revenue was $4,368,916 (up 355%) and net loss from continuing operations was $31,736,245, driven mainly by a non-cash warrant fair-value loss. Cash fell to $866,170 from $4,889,824. The CEO says the company will ask regulators to revoke the cease trade order, so shares are currently under one. The Sun Valley sale completed March 4, 2022, resolving the 2021 non-binding agreement. The company raised $3.0 million and $2.1 million of convertible debentures in January and March 2022 and closed two Medi-Collective clinics.
Q2 2021 results: revenue from continuing operations of $861,826 versus $85,775 a year earlier, net loss from continuing operations of $412,209, and cash of $5,191,944 at June 30, 2021. The company now describes itself as an integrated healthcare company, and the release says it paid off $2 million in debt. In July 2021 it agreed non-bindingly to sell Sun Valley, the business bought in 2019, back to its previous owners for $1,000,000 in Empower securities. On July 30, 2021 it bought Medi+Sure Canada for CAD$3.5M (CAD$1,250,000 cash plus 4,582,483 shares), which dilutes holders. This reverses the 2019 Sun Valley deal.
Refiles the audited 2017 statements of the clinic business (then S.M.A.A.R.T Holdings) and the March 31, 2018 interim statements, as part of the July 2019 catch-up. At December 31, 2017 total assets were $629,802, liabilities $5,436,664 and shareholders' equity negative $4,806,862, with 48,337,225 shares. The 2017 net loss was $3,109,921 and the auditors flagged going-concern uncertainty. This continues the refiling of older documents and shows deficits predate the 2018 listing.
Files a notice, dated April 1, 2019, that the company has been out of oil and gas activities since June 12, 2015, formally closing the Adira-era energy business. It also files a material change report: on April 2, 2019 the company closed $799,500 of convertible debentures and 21,115,000 units at $0.10 for $2,115,000, a total of $2,914,500. The press release says AgraFlora Organics made a $1,000,000 investment and that proceeds are for strategic acquisitions and working capital. The new shares and convertible debt dilute existing holders. The debenture figure differs from the $779,500 raise in the earlier context, so the exact amount is unclear.
Refiles nine-month statements to September 30, 2018 (approved November 29, 2018). Clinic revenues were $894,477 against $1,215,329 a year earlier, with a net loss of $5,132,848 including a $1,143,660 listing expense and $1,443,928 of share-based payments. Total assets were $1,545,574 and shareholders' equity was negative $2,825,585, with 74,966,957 shares and a going-concern note. Equity remains negative and the loss widened compared with the prior year's nine months ($2,295,382).
Refiles the MD&A, interim financial statements and certifications for the six months to June 30, 2018, the same period as the amended statements filed earlier the same day. The MD&A describes 14 clinics in Oregon and Washington and a Chicago clinic scheduled for Q3 2018. It continues the catch-up refiling of 2018 documents.
Files business acquisition reports confirming the Sun Valley deal closed April 30, 2019, for aggregate value of $3,960,000. The consideration was US$775,000 cash (US$150,000 held back), 22,058,823 shares at US$0.136 (14,705,882 in escrow, vesting quarterly over 36 months), and minority buyouts for US$12,318 cash, 350,602 shares and a US$125,000 4% note due July 31, 2019. Dustin Klein joined the board. The cash was funded by a convertible debenture raise of $779,500 on April 1, 2019. This resolves the January term sheet; the new shares dilute existing holders.
Files a January 28, 2019 report on a non-binding term sheet to buy Sun Valley Certification Clinics Holdings LLC (six clinics plus a franchise business). Proposed terms: US$625,000 cash at closing plus a US$150,000 holdback, US$1,000,000 in shares, and up to US$2,000,000 more in shares vesting over 36 months if performance targets are met. Closing depended on a definitive agreement, due diligence, approvals, and raising at least US$3,000,000 in debt or equity, with expected closing around March 15, 2019. Later filings show the deal was completed April 30, 2019.
Refiles the MD&A for the nine months to September 30, 2018, amended only to correct the date stated after the first paragraph to September 30, 2018, with refiled certifications. It describes a clinic business of 14 clinics in Oregon and Washington plus a recently opened Chicago clinic, built on the June 2015 purchase of Presto Quality Care assets. This continues the pattern of refiling 2018 documents in July 2019.
Files a June 2019 package: a material change report on 7,700,000 stock options (exercisable at $0.14, 7,000,000 for five years and 700,000 for three years) and 7,400,000 bonus shares granted to directors, officers, employees and consultants, with most bonus shares vesting over three years. It also files the annual financial statements and MD&A for 2018, Q1 2019 interim statements (original and amended) and related certifications; their figures are not in the text provided. The grants add to the share count and so dilute existing holders.
Files material change reports on the second tranche of a May 3, 2019 private placement: unsecured convertible debentures with 6.0% interest maturing May 3, 2020 (convertible at $0.11 per unit), and 5,762,500 units at $0.10 each for $576,250 gross. Each unit includes a share and a warrant exercisable at $0.16 for two years. The proceeds are meant for strategic acquisitions and working capital, and the release also reports the Sun Valley acquisition as completed. The filing shows the debenture total as $207,070 in one place and $207,270 in another, and the combined total as $783,250 in one place and $783,520 in another, so the exact figures are inconsistent in the text. New shares and convertible debt mean dilution for existing holders.
Files a notice, dated June 22, 2018, explaining how the company became Empower Clinics. It acquired SMAART Holdings in a reverse take-over completed April 23, 2018: SMAART's securities were swapped one-for-one for company shares, the company changed its name and consolidated its shares 6.726254 to one, and shares began trading on the CSE on April 30, 2018. This answers the open question of how the Adira shell relates to the clinic business: the clinic business was acquired through SMAART, and the former Adira company is the continuing entity.
Refiles interim statements for the six months to June 30, 2018, amended only to add the June 30, 2017 equity balances. Empower Clinics is described as formerly S.M.A.A.R.T Holdings Inc. and reports clinic revenues of $614,627, a net loss of $4,754,191 including a $1,143,660 listing expense, and negative shareholders' equity of $2,639,126. It had 74,966,957 shares at June 30, 2018, a going-concern note, and a secured loan of $696,005. The statements show a clinic business, not oil and gas; the link to the Adira history is not explained in the text. Mathew Lee signs as CFO.
The registrant now appears as Empower Clinics Inc. (formerly Adira Energy Ltd.) at a Vancouver address, with Carly Krivanek signing as CFO. The filing itself is interim financial statements, MD&A and certifications, and gives no reason for the name change. The new name and address are a break from the Israel offshore exploration story.
Routine annual filing of audited financial statements, MD&A and certifications, now signed by Alan Rootenberg as CFO instead of Gadi Levin. No figures are in the cover text.
Files oil and gas reserves data (Form 51-101F1) and the management and directors' report on it (Form 51-101F3). The reserve figures and the properties covered are not in the text provided.
Routine filing of interim financial statements, MD&A and certifications. The principal office address is now 4101 Yonge Street West, Suite 706, Toronto, instead of 120 Adelaide Street West.
Routine annual filing of audited financial statements, MD&A and certifications. Unlike earlier years, no oil and gas disclosure forms are listed. No figures are in the cover text.
Routine annual filing: audited annual financial statements, MD&A, oil and gas disclosure forms, a participation fee form and certifications. No figures are in the cover text.